Novartis is looking to put artificial intelligence tools on the desktops of each of its research associates, and it’s tapping Microsoft to do it.

Pfizer is planning to establish a multinational network of digital research hubs with a focus on artificial intelligence and big data analytics.

Richter has announced the launch of Terrosa (teriparatide) in Europe, a biosimilar of Eli Lilly’s Forsteo (teriparatide).

Sanofi could use a boost from new launches, but it apparently doesn’t think it’ll get what it needs from diabetes hopeful Zynquista. It’s calling it quits on the drug, which the FDA rejected for Type 1 diabetes in March, after reporting Type 2 results analysts called “equivocal.”

PARIS (Reuters) – French healthcare company Sanofi has teamed up with Google to work on innovations, aimed at using emerging data technologies to change how medicines and health services will be delivered in future.

(Reuters) – AstraZeneca Plc said on Tuesday it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as $276 million.

Another Novartis ingredient operation is being hived off as the Swiss drugmaker continues its drive to lop off manufacturing jobs to improve margins. This time it is selling an operation in China that it opened 10 years ago.

Novartis granting Sandoz independence within the company sounds a lot like what Pfizer did with its own generics business before it struck a deal to merge the unit with Mylan.

Mumbai, India, June 24, 2019: GlenmarkPharmaceuticals Ltd (Glenmark), a research-led globalintegrated pharmaceutical company, today announced thatits Brazilian subsidiary, Glenmark Farmacêutica Ltdahas entered into an exclusive partnershipagreement with Novartis Biosciences S.A, a subsidiary of NovartisAG, for three respiratory productsindicatedtowards treatment of the symptoms of chronic obstructive pulmonary disease (COPD)in Brazil.This agreement will be effective from July 01, 2019 onwards.

Novartis has announced that a phase III QUARTZ study of its investigational inhaled combination treatment, QMF149, has met primary and key secondary endpoints in patients with inadequately controlled asthma. The once-daily, fixed-dose treatment demonstrated significant improvements in lung function and asthma control versus inhaled corticosteroid (ICS) alone.